Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib

Br J Haematol. 2021 Nov;195(4):637-641. doi: 10.1111/bjh.17732. Epub 2021 Aug 16.

Carlos Solano de la Asunción¹, María José Terol^{2

3}, Ana Saus², Beatriz Olea¹, Estela Giménez¹, Eliseo Albert¹, Javier López-Jiménez⁴, Rafael Andreu⁵, Dolores García⁶, Laura Fox⁷, María José Remigia², Paula Amat^{2

3}, Carlos Solano^{2

3}, David Navarro^{1

8}

¹ Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
² Hematology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
³ Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
⁴ Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
⁵ Hematology Service, Hospital Universitario Politécnico "La Fe", Valencia, Spain.
⁶ Hematology Service, Hospital Morales Meseguer, Murcia, Spain.
⁷ Hematology Service, Hospital Vall d´Hebron, Barcelona, Spain.
⁸ Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.

No abstract available

Keywords: CMV; CMV CD4+ T cells; CMV CD8+ T cells; CMV DNAemia; chronic lymphocytic leukaemia; ibrutinib.

Publication types